University of Melbourne

File(s) not publicly available

Reason: data file not attached

A feasibility study of lorazepam for anxiety in palliative care (LORAZEPAM Study)

posted on 2023-05-17, 05:30 authored by Dr Nicola Atkin, Professor Brian Le, Professor Jennifer Philip
Demographic data for 15 adult patients with advanced cancer or advanced life-limiting disease and persistent or recurrent anxiety causing clinically significant distress or functional impairment at time of enrolment. 11 patients randomised to regular lorazepam treatment arm, 4 randomised to placebo, and treated for up to 12 weeks. Data collected at baseline, week 1,2,4,8,12 and follow-up at week 16 unless early discontinuation. Data includes anxiety measures (HADS-A, PROMIS 7a short form, PGIC), functional status (AKPS), other symptoms (ESAS), health-related quality of life (EQ 5D 5L), sleepiness (ESS), other adverse events and feasibility outcome data (recruitment, retention, completion of assessments, survival, acceptability, burden).


Resource Type

Individual Participant Data (IPD)

Institution name

Peter MacCallum Cancer Centre


Victoria, Australia

Contact Organisation


Contact Organisation Identifier

Study Identifier

Date Collected


HeSANDA Version

HeSANDA 1.0.0